Patrick Wood
Stock Analyst at Morgan Stanley
(2.00)
# 2,864
Out of 5,182 analysts
121
Total ratings
37.5%
Success rate
-4.09%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $23 → $25 | $19.87 | +25.82% | 7 | Mar 2, 2026 | |
| MDLN Medline | Maintains: Overweight | $48 → $52 | $44.19 | +17.67% | 2 | Mar 2, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $80 → $85 | $61.00 | +39.34% | 9 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $130 → $118 | $56.85 | +107.56% | 8 | Feb 5, 2026 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $76 → $83 | $61.52 | +34.92% | 7 | Dec 8, 2025 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $123 → $135 | $97.08 | +39.06% | 3 | Dec 2, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $9 → $10 | $7.38 | +35.50% | 3 | Dec 2, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $56 → $51 | $24.83 | +105.40% | 4 | Dec 2, 2025 | |
| DXCM DexCom | Upgrades: Overweight | $63 → $75 | $60.04 | +24.92% | 10 | Dec 2, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $197 → $210 | $146.31 | +43.53% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $19 → $15 | $16.62 | -9.75% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $14 → $21 | $16.30 | +28.83% | 9 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $80 | $73.48 | +8.87% | 5 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $276 → $295 | $212.25 | +38.99% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $81 | $83.33 | -2.80% | 9 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $67.44 | +52.73% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $135.85 | -47.00% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $119.89 | +44.30% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $171.39 | +84.96% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $27.29 | +35.58% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $154.08 | - | 5 | Dec 11, 2017 |
Tandem Diabetes Care
Mar 2, 2026
Maintains: Equal-Weight
Price Target: $23 → $25
Current: $19.87
Upside: +25.82%
Medline
Mar 2, 2026
Maintains: Overweight
Price Target: $48 → $52
Current: $44.19
Upside: +17.67%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Equal-Weight
Price Target: $80 → $85
Current: $61.00
Upside: +39.34%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $130 → $118
Current: $56.85
Upside: +107.56%
The Cooper Companies
Dec 8, 2025
Maintains: Equal-Weight
Price Target: $76 → $83
Current: $61.52
Upside: +34.92%
TransMedics Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $123 → $135
Current: $97.08
Upside: +39.06%
RxSight
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $7.38
Upside: +35.50%
PROCEPT BioRobotics
Dec 2, 2025
Maintains: Overweight
Price Target: $56 → $51
Current: $24.83
Upside: +105.40%
DexCom
Dec 2, 2025
Upgrades: Overweight
Price Target: $63 → $75
Current: $60.04
Upside: +24.92%
Becton, Dickinson and Company
Dec 2, 2025
Maintains: Overweight
Price Target: $197 → $210
Current: $146.31
Upside: +43.53%
Dec 2, 2025
Maintains: Underweight
Price Target: $19 → $15
Current: $16.62
Upside: -9.75%
Dec 2, 2025
Upgrades: Overweight
Price Target: $14 → $21
Current: $16.30
Upside: +28.83%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $73.48
Upside: +8.87%
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $212.25
Upside: +38.99%
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $83.33
Upside: -2.80%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $67.44
Upside: +52.73%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $135.85
Upside: -47.00%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $119.89
Upside: +44.30%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $171.39
Upside: +84.96%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $27.29
Upside: +35.58%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $154.08
Upside: -